Detail
| LncRNA Name | MYCLo-5 |
| Synonyms | LPP-AS2, MYCLo-5, MYCLo-6 |
| Region | GRCh38_3:188151206-188154057 Sequence |
| Ensembl | ENSG00000270959 |
| RefSeq | NR_036497 |
| Circulating | ✘ |
| Drug-resisitant | ✘ |
| Prognostic | ✘ |
| MiRNA | ✘ |
| Variant | ✘ |
| TF | ✔ |
| Methylation | ✘ |
| Cancer Name | prostate cancer |
| ICD-0-3 | C61.9 |
| Methods | qPCR, Flow cytometry assay, Cell proliferation assay etc. |
| Sample | cell lines (HCT116, RKO, HT29, A549, PC3, MCF7 and SKBR3, SK-HEP-1 and HepG2) |
| Expression Pattern | down-regulated |
| Function Description | Of the tested cell lines, MYCLo-4 was upregulated by MYC knockdown in HCT116 (CRC), RKO (CRC), HT29 (colorectal adenocarcinoma), A549 (Lung carcinoma) and PC3 (prostate cancer). The other 2 lncRNAs, MYCLo-5 and -6 were also induced by MYC repression in various cancer types such as CRC (HCT116, RKO and HT29), lung cancer (A549), prostate cancer (PC3), breast cancer (MCF7 and SKBR3) and hepatocellular carcinoma (SK-HEP-1 and HepG2). |
| Pubmed ID | 26003165 |
| Year | 2015 |
| Title | MYC-repressed long noncoding RNAs antagonize MYC-induced cell proliferation and cell cycle progression. |
| External Links |
| Links for MYCLo-5 | GenBank HGNC lncrnadb Noncode |
| Links for prostate cancer | Omim Cosmic |
CopyRight © College of Bioinformatics Science and Technology, Harbin Medical University, China.